TNON Tenon Medical, Inc.
Surgical & Medical Instruments & Apparatus · Nasdaq · SEC CIK 1560293 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY72.3%
TTM net income YoY-32.7%
TTM EPS YoY162.1%
Revenue 3-yr CAGR32.5%
Net income 3-yr CAGR—
Margins
Gross margin66.9%
Operating margin-225.9%
Net margin-305.1%
FCF margin-193.1%
EBITDA margin-220.7%
Returns
ROE-242.5%
ROA-128.0%
ROIC (approx.)-863.4%
Asset turnover0.42x
Leverage & solvency
Liabilities / assets43.1%
Debt / equity0.00x
Current ratio2.93x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.61x
Accruals ratio-50.2%
Payout ratio—
Capex / revenue7.7%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $3.94M | $3.28M |
| Cost of revenue | $1.59M | $1.57M |
| Gross profit | $2.36M | $1.71M |
| R&D expense | $2.15M | $2.60M |
| SG&A expense | $6.97M | $7.76M |
| Operating income | -$12.79M | -$13.77M |
| Interest expense | — | $34,000 |
| Pretax income | -$12.56M | -$13.67M |
| Net income | -$12.56M | -$13.67M |
| EBITDA | -$12.53M | -$13.36M |
| EPS (basic) | -1.70 | -11.26 |
| EPS (diluted) | -1.70 | -11.26 |
| Weighted avg. shares (diluted) | 7,384 | 1,214 |
| Balance sheet | ||
| Cash & equivalents | $3.76M | $6.54M |
| Receivables | $1.70M | $863,000 |
| Inventory | $1.05M | $606,000 |
| Current assets | $6.77M | $8.21M |
| PP&E, net | $918,000 | $752,000 |
| Goodwill | $2.41M | — |
| Intangibles | $485,000 | — |
| Total assets | $10.76M | $9.84M |
| Current liabilities | $3.21M | $1.87M |
| Total liabilities | $5.72M | $3.87M |
| Shareholders' equity | $5.04M | $5.97M |
| Shares outstanding | 310,036 | 3.14M |
| Cash flow statement | ||
| Operating cash flow | -$10.74M | -$9.88M |
| Capital expenditure | $273,000 | $186,000 |
| Free cash flow | -$11.02M | -$10.06M |
| Investing cash flow | -$1.02M | -$186,000 |
| Financing cash flow | $8.99M | $14.12M |
| Depreciation & amortization | $262,000 | $408,000 |
| Stock-based compensation | $1.69M | $3.85M |
Free plan shows the latest 2 periods; Pro shows all 5 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.